



## **Alkermes to Host Conference Call to Discuss Q2 Financial Results**

November 3, 2003

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 3, 2003--Alkermes, Inc., (Nasdaq: ALKS) will host a conference call at 4:30pm EST on Wednesday, November 5, 2003 to discuss the Company's financial results for the second quarter. Management will review the quarter and provide an update on the company.

The conference call may be accessed by dialing 1-888-792-1093 for domestic callers and 1-703-871-3597 for international callers. The conference call ID number is 314038. Additionally, the call will be webcast on the investor relations section of Alkermes' website at [www.alkermes.com](http://www.alkermes.com) and archived on the site until Monday, November 10, 2003 at 5:00pm.

A replay of the conference call will be available from 7:30pm EST on November 5, 2003 through 5:00pm EST on November 9, 2003, and may be accessed by visiting Alkermes' website or by dialing 1-888-266-2081 for domestic callers and 1-703-925-2533 for international callers. The replay access code is 314038.

Alkermes, Inc. is an emerging pharmaceutical company developing products based on its sophisticated drug delivery technologies to enhance therapeutic outcomes. Our areas of focus include: controlled, extended-release of injectable drugs utilizing our ProLease(R) and Medisorb(R) delivery systems and the development of inhaled pharmaceutical products based on our proprietary Advanced Inhalation Research, Inc., ("AIR(R)") pulmonary delivery system. Our business strategy is twofold. We partner our proprietary technology systems and drug delivery expertise with many of the world's finest pharmaceutical companies and also develop novel, proprietary drug candidates for our own account. In addition to our Cambridge, Massachusetts headquarters, research and manufacturing facilities, we operate research and manufacturing facilities in Ohio.

CONTACT: Alkermes, Inc.  
Rebecca Peterson, 617-583-6378

SOURCE: Alkermes, Inc.